Preserving Clinical Trial Integrity During the Coronavirus Pandemic

JAMA. 2020 Jun 2;323(21):2135-2136. doi: 10.1001/jama.2020.4689.

Authors

Mary M McDermott^{1

2}, Anne B Newman³

Affiliations

¹ Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
² Deputy Editor.
³ Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.

PMID: 32211830
DOI: 10.1001/jama.2020.4689

No abstract available

MeSH terms

Appointments and Schedules
Betacoronavirus*
COVID-19
Cell Phone
Coronavirus Infections / epidemiology*
Coronavirus Infections / prevention & control
Electronic Mail
Guidelines as Topic
Humans
Intention to Treat Analysis
Medical Staff*
Pandemics / prevention & control
Patient Safety*
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / prevention & control
Quality Control
Randomized Controlled Trials as Topic / standards*
Randomized Controlled Trials as Topic / statistics & numerical data
Risk Assessment
SARS-CoV-2
Surveys and Questionnaires
Transportation of Patients / methods
Treatment Outcome